Skip to main content

Table 3 Some studies exploring the expression of MUC2 against other mucins in PMP (2002–2012)

From: Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects

Study

Year

Number of PMP cases

Percentage of cases exhibiting the expression of mucins

MUC2

Other forms of mucins

O’Connell et al. [8]

2002

100

98%

MUC5AC 95%

O’Connell et al. [56]

2002

25

96%

MUC5AC 92%

Mohamed et al. [126]

2004

33

97%

MUC1 57.5%

Kinkor et al. [127]*

2005

3

?

-

Nonaka et al. [128]

2006

42

100%

MUC5AC 100%

Mall et al. [122]

2007

1

100%

MUC5AC 100%

MUC5B 100%

Ferreira et al. [129]

2008

7

100%

MUC1 28.6%

MUC5AC 100%

MUC6 28.6%

Semino-Mora et al. [58]**

2008

16

N/A‡

N/A‡‡

Baratti et al. [61]***

2009

85

100%

MUC5AC 87.5%

Flatmark et al. [59]

2010

5

100%

MUC1 0%

MUC5AC 40%

MUC4 100%

Guo et al. [60]

2011

35

94.3%

MUC1 0%

Mall et al. [123]

2011

1

100%

MUC1 0%

MUC4 100%

MUC5AC 100%

MUC5B 100%

MUC6 0%

Chang et al. [130]****

2012

4

64%†

MUC5AC 43%††

  1. *Full-text article, in Czech, not accessible. Results of IHC study not available.
  2. **This study reports the expression of MUC2 and MUC5A as the volumetric density of apomucin (Vvi/104 μm) in such compartments of DPAM and PMCA tissues as epithelium, lymphoid aggregates, stroma vessels and free mucin, respectively, as follows:
  3. ‡MUC2: in DPAM: 264 ± 60, 47 ± 16, 31 ± 14 and 261 ± 51; in PMCA: 356 ± 90, 170 ± 26, 117 ± 25 and 1043 ± 282.
  4. ‡‡MUC5AC: in DPAM: 90 ± 13, 345 ± 20, 65 ± 17, 37 ± 6; in PMCA: 56 ± 12, 246 ± 17, 50 ± 15 and 48 ± 9.
  5. ***The percentages shown for this study are numerical estimations of data originally presented in a column graph.
  6. ****In this study, among a total of 14 patients with mucinous adenocarcinoma, 4 cases have reportedly exhibited PMP syndrome. Results of the expression of MUC2 and MUC5AC, however, are reported in total, with no data individually available regarding the PMP cases.
  7. †, ††Data shown is the percentage of MUC2/MUC5AC expression in all patients with mucinous adenocarcinoma, including PMP ones.